868669-87-8

Basic information

• Product Name: (4S,5R)-1-{(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propanoyl}-3,4-dimethyl-5-phenylimidazolidin-2-one
• Synonyms: (4S,5R)-1-{(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propanoyl}-3,4-dimethyl-5-phenylimidazolidin-2-one
• CAS NO: 868669-87-8
• Molecular Weight: 519.613
• Mol File: 868669-87-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (4S,5R)-1-{(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propanoyl}-3,4-dimethyl-5-phenylimidazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (4S,5R)-1-{(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propanoyl}-3,4-dimethyl-5-phenylimidazolidin-2-one(868669-87-8)
• EPA Substance Registry System: (4S,5R)-1-{(3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propanoyl}-3,4-dimethyl-5-phenylimidazolidin-2-one(868669-87-8)

Safety Data

• Hazardous Substances Data: 868669-87-8(Hazardous Substances Data)

Upstream product

• 833491-23-9 (4R,5S)-1,5-dimethyl-3-{(2E)-3-[1-(methylsulfonyl)piperidin-4-yl]prop-2-enoyl}-4-phenylimidazolidin-2-one 
• 62351-47-7 3,5-difluorophenylmagnesium bromide 
• 833491-33-1 3-(N-methanesulphonylpiperidin-4-yl)propenoic acid 

Downstream Products

• 718610-25-4 (R) 3-(1-methanesulphonylpiperidin-4-yl)-3-[3,5-difluorophenyl]propionaldehyde 
• 872879-86-2 [3H]-AZD₅₆₇₂ 
• 718610-74-3 (3R)-3-(3,5-difluorophenyl)-3-[1-(methylsulfonyl)piperidin-4-yl]propan-1-ol 

Relevant articles and documents

Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis

Modifications to a series of potent and selective substituted 1-(3,3-diphenylpropyl)-piperidine phenylacetamide CCR5 antagonists were explored with the aim of reducing affinity at the hERG cardiac ion channel. Replacement of one aromatic ring in the diphe

CHEMICAL COMPOUNDS I

Compounds of formula (I) compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).

CHEMICAL COMPOUNDS

Compounds of formula (I): wherein: when X is NR5, Y is absent or is CH2; when X is CH2, Y is absent, CH2, NR6, O, S, S(O) or S(O)2; Z is a 5- or 6-membered heterocyclyl ring; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).